Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A C Collier

Showing results (101-110 of 131) with videos related to

Pageof 14
Sort By:
The Journal of Infectious Diseases|August 19, 2000
Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333M F Para, D V Glidden, R W Coombs, et al.
Journal of Acquired Immune Deficiency Syndromes|February 1, 1994
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3M A Fischl, L Resnick, R Coombs, et al.
Brain, Behavior, & Immunity - Health|March 21, 2022
Peripheral inflammation and depressed mood independently predict neurocognitive worsening over 12 yearsRonald J Ellis, Robert K Heaton, Bin Tang, et al.
Annals of Internal Medicine|May 15, 1990
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials GroupM A Fischl, D D Richman, N Hansen, et al.
AIDS (London, England)|July 1, 1995
The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudineM A Jacobson, V De Gruttola, M Reddy, et al.
Annals of Neurology|April 1, 1993
Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials GroupJ J Sidtis, C Gatsonis, R W Price, et al.
The New England Journal of Medicine|October 11, 1990
A pilot study of low-dose zidovudine in human immunodeficiency virus infectionA C Collier, S Bozzette, R W Coombs, et al.
The Journal of Infectious Diseases|April 25, 2001
Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDSM M Berrey, T Schacker, A C Collier, et al.
Annals of Internal Medicine|July 4, 2001
Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV diseaseE L Murphy, A C Collier, L A Kalish, et al.
The New England Journal of Medicine|August 17, 1995
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials GroupP A Volberding, S W Lagakos, J M Grimes, et al.
Pageof 14

Showing results (101-110 of 131) with videos related to

Sort By:
Pageof 14
The Journal of Infectious Diseases|August 19, 2000
Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333M F Para, D V Glidden, R W Coombs, et al.
Journal of Acquired Immune Deficiency Syndromes|February 1, 1994
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3M A Fischl, L Resnick, R Coombs, et al.
Brain, Behavior, & Immunity - Health|March 21, 2022
Peripheral inflammation and depressed mood independently predict neurocognitive worsening over 12 yearsRonald J Ellis, Robert K Heaton, Bin Tang, et al.
Annals of Internal Medicine|May 15, 1990
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials GroupM A Fischl, D D Richman, N Hansen, et al.
AIDS (London, England)|July 1, 1995
The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudineM A Jacobson, V De Gruttola, M Reddy, et al.
Annals of Neurology|April 1, 1993
Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials GroupJ J Sidtis, C Gatsonis, R W Price, et al.
The New England Journal of Medicine|October 11, 1990
A pilot study of low-dose zidovudine in human immunodeficiency virus infectionA C Collier, S Bozzette, R W Coombs, et al.
The Journal of Infectious Diseases|April 25, 2001
Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDSM M Berrey, T Schacker, A C Collier, et al.
Annals of Internal Medicine|July 4, 2001
Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV diseaseE L Murphy, A C Collier, L A Kalish, et al.
The New England Journal of Medicine|August 17, 1995
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials GroupP A Volberding, S W Lagakos, J M Grimes, et al.
Pageof 14